Showing results (101-110 of 258) with videos related to

Sort By:
Pageof 26
Hormones (Athens, Greece)|April 30, 2014
Endothelial progenitor cells as a cardiometabolic risk factor marker in prediabetesAngeliki Angelidi, Andreas Melidonis, Ioannis Protopsaltis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2011
Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinomaEirini Pectasides, Theodore Rampias, Panteleimon Kountourakis, et al.
Plos One|April 12, 2014
Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC)Eirini Pectasides, Theodoros Rampias, Clarence Sasaki, et al.
Annals of Hematology|September 15, 2010
Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1→HIF-1α pathwayPinelopi Argyriou, Sotirios G Papageorgiou, Varvara Panteleon, et al.
Hepato-Gastroenterology|May 30, 2008
Fibrous ring formation in cirrhotics treated with band ligationChristos Triantos, Spilios Manolakopoulos, Jiannis Anastasiou, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 27, 2011
Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variablesYalai Bai, Juliana Tolles, Huan Cheng, et al.
Oncology Letters|July 12, 2012
Correlation of CYP1A1, GSTP1 and GSTM1 gene polymorphisms and lung cancer risk among smokersKyriaki Pliarchopoulou, Gerasimos Voutsinas, George Papaxoinis, et al.
Haematologica|September 5, 2007
A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4Serena Valsami, Vassiliki Pappa, Dimitra Rontogianni, et al.
The Laryngoscope|October 23, 2012
Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinomaHatim Husain, Amanda Psyrri, Ana Markovic, et al.
International Journal of Gastrointestinal Cancer|May 10, 2005
A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancerThomas Makatsoris, Haralabos P Kalofonos, Gerasimos Aravantinos, et al.
Pageof 26